Novabay Pharmaceuticals (NBY) Stock Price, Quote & News

Company Profile

NovaBay Pharmaceuticals, Inc. does not have significant operations. Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 510 899 8800

Fax: 510 474 1577

Website: novabay.com

Address:

2000 Powell Street, Suite 1150, eleventh floor, Emeryville, United States

Bigdubs Dec. 24 at 9:44 PM

$NBY Borrow is near 100%. If you’re long and not lending shares, you’re leaving real money on the table… That’s roughly ~1/70th of my cost basis per day at current rates. We’re waiting on a defined catalyst. Getting paid while waiting is pretty sweet. Risk remains, but an offering ahead of the event makes little sense, and positioning reflects that. Do your own DD.

0 · Reply

SaySomethingNice Dec. 24 at 6:45 PM

$KALA $NBY RAN UP... $INDP RSN UP $KALA IS UP NEXT, 👇 DAVID LAZAR IS THE MASTERMIND BEHIND MULTIPLE MERGERS, ACQUISITIONS, FIXING DISTRESS COMPANIES.. - Imo

0 · Reply

ACInvestorBlog Dec. 24 at 5:46 PM

$KALA seems to be bottoming out. With each passing day I feel more positive about this beaten down small bio name. I see this stock trading well over $1 in the near future. I have a habit of seeing these big gains before anyone else, and I don't think it will be any different this time around. Lets see how it plays out in the next sessions. Good price action volume today. David Lazar did a great job on $NBY recovering.

0 · Reply

ACInvestorBlog Dec. 24 at 5:45 PM

0 · Reply

ACInvestorBlog Dec. 24 at 3:20 PM

$KALA is here ( $NBY chart )

0 · Reply

ACInvestorBlog Dec. 24 at 3:18 PM

$KALA is the $NBY 2.0 imho David Lazar is the master in recovering companies

1 · Reply

SaySomethingNice Dec. 24 at 3:04 PM

$KALA $NBY $INDP $KALA Investors ITCHING to get in imminent. Look how the volumes went from 150k to OVER 900K+ shares traded blink of an eye.. INVESTORS KNOWS DAVID LAZAR PAST SUCCESSFUL HISTORY OF MERGING AND FIXING COMPANIES IN DISTRESS. $KALA : CURRENT CEO ✅️ $INDP : TOOK OVER AS CEO ✅️ $NBY : WAS CEO A FEW MONTHS AGO. $KALA IS THE CHEAPEST PPS, ATM. Question is.. FOR HOW LONG BEFORE SHE'S GONE? - Imo

0 · Reply

SaySomethingNice Dec. 24 at 2:53 PM

$KALA David Lazar is the master of merger and fixing companies in distress. $NBY ✅️ $INDP tbd $KALA title: NEW CEO DECEMBER 27TH: NEW DIRECTORS NAMES tba.. Glta - IMO

0 · Reply

RegionalRuler Dec. 24 at 11:34 AM

$NBY The longer-term setup revolves around whether operational decisions reinforce credibility with the market. The window for proof-of-execution is narrowing.

0 · Reply

SaySomethingNice Dec. 24 at 4:07 AM

$KALA Almost 10k+ watchers lurking $KALA DAVID IS THE MASTER OF TURNING NASDAQ PUBLIC COMPANIES AROUND... Below 🔥 👇 $NBY $KALA $INDP DYOR & DD - Imo..

0 · Reply

NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards

Sep 18, 2025, 4:30 PM EDT - 3 months ago

NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

Aug 26, 2025, 4:05 PM EDT - 4 months ago

NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

Aug 19, 2025, 5:25 PM EDT - 4 months ago

NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Mar 7, 2025, 6:50 AM EST - 10 months ago

NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders

Jan 23, 2025, 8:00 AM EST - 11 months ago

NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal

Dec 19, 2024, 6:50 AM EST - 1 year ago

NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

Dec 9, 2024, 6:50 AM EST - 1 year ago

NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting

Nov 22, 2024, 4:05 PM EST - 1 year ago

NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024

Nov 15, 2024, 8:00 AM EST - 1 year ago

Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand

Nov 7, 2024, 4:05 PM EST - 1 year ago

NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price

Oct 29, 2024, 8:00 AM EDT - 1 year ago

NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals

Sep 20, 2024, 8:00 AM EDT - 1 year ago

NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets

Aug 13, 2024, 11:29 PM EDT - 1 year ago

NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:05 PM EDT - 1 year ago

NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 1, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

Jul 30, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales

Jul 29, 2024, 4:05 PM EDT - 1 year ago

NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option

Jul 26, 2024, 8:30 AM EDT - 1 year ago

NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering

Jul 16, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day

Jul 11, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million

Jul 1, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

Jun 28, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions

Jun 7, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American

May 29, 2024, 5:22 PM EDT - 1 year ago

NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates

May 13, 2024, 8:30 AM EDT - 1 year ago

NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms

May 11, 2024, 1:59 PM EDT - 1 year ago

NovaBay Pharmaceuticals, Inc. (NBY) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results

May 7, 2024, 8:00 AM EDT - 1 year ago

NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon

May 3, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024

Apr 22, 2024, 6:57 AM EDT - 1 year ago

NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales

Apr 19, 2024, 6:00 PM EDT - 1 year ago

NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity

Apr 17, 2024, 6:59 AM EDT - 1 year ago

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses

Mar 26, 2024, 6:43 PM EDT - 1 year ago

NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 4:05 PM EDT - 1 year ago

NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results

Mar 25, 2024, 6:38 PM EDT - 1 year ago

NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024

Mar 14, 2024, 8:00 AM EDT - 1 year ago

NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023

Jan 30, 2024, 9:00 AM EST - 2 years ago

NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales

Jan 9, 2024, 9:15 AM EST - 2 years ago

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network

SNOA

Dec 6, 2023, 6:50 AM EST - 2 years ago

NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

Nov 9, 2023, 11:43 PM EST - 2 years ago

NovaBay Pharmaceuticals, Inc. (NBY) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 4:05 PM EST - 2 years ago

NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results

Nov 2, 2023, 6:50 AM EDT - 2 years ago

NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023

Oct 11, 2023, 8:00 AM EDT - 2 years ago

NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs

Oct 2, 2023, 6:50 AM EDT - 2 years ago

NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

Sep 14, 2023, 8:00 AM EDT - 2 years ago

NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

Sep 11, 2023, 8:00 AM EDT - 2 years ago

NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

Bigdubs Dec. 24 at 9:44 PM

0 · Reply

SaySomethingNice Dec. 24 at 6:45 PM

$KALA $NBY RAN UP... $INDP RSN UP $KALA IS UP NEXT, 👇 DAVID LAZAR IS THE MASTERMIND BEHIND MULTIPLE MERGERS, ACQUISITIONS, FIXING DISTRESS COMPANIES.. - Imo

0 · Reply

ACInvestorBlog Dec. 24 at 5:46 PM

0 · Reply

ACInvestorBlog Dec. 24 at 5:45 PM

0 · Reply

ACInvestorBlog Dec. 24 at 3:20 PM

$KALA is here ( $NBY chart )

0 · Reply

ACInvestorBlog Dec. 24 at 3:18 PM

$KALA is the $NBY 2.0 imho David Lazar is the master in recovering companies

1 · Reply

SaySomethingNice Dec. 24 at 3:04 PM

0 · Reply

SaySomethingNice Dec. 24 at 2:53 PM

$KALA David Lazar is the master of merger and fixing companies in distress. $NBY ✅️ $INDP tbd $KALA title: NEW CEO DECEMBER 27TH: NEW DIRECTORS NAMES tba.. Glta - IMO

0 · Reply

RegionalRuler Dec. 24 at 11:34 AM

$NBY The longer-term setup revolves around whether operational decisions reinforce credibility with the market. The window for proof-of-execution is narrowing.

0 · Reply

SaySomethingNice Dec. 24 at 4:07 AM

$KALA Almost 10k+ watchers lurking $KALA DAVID IS THE MASTER OF TURNING NASDAQ PUBLIC COMPANIES AROUND... Below 🔥 👇 $NBY $KALA $INDP DYOR & DD - Imo..

0 · Reply

TheBullishOne007 Dec. 24 at 1:16 AM

$INDP Another Lazar effect. On a roll with this guy. 👍 $NBY $KALA

2 · Reply

PTI127 Dec. 23 at 10:36 PM

$NBY

0 · Reply

Bigdubs Dec. 23 at 8:02 PM

$NBY Some pullback after a hot run no problem. No offering will happen till the plan is released by Michael Kazley. Any offering FUD before that is hearsay.

0 · Reply

YFZ450 Dec. 23 at 2:34 PM

$NBY dead and offering any minute... i did think they wanted it higher if they dump their full wad but it looks like that's all she wrote

0 · Reply

IBOTTheDipAndTheDipWon Dec. 23 at 2:26 PM

$NBY Are the cracks finally starting to appear?

0 · Reply

MisanthropicAlien Dec. 23 at 2:21 PM

$NBY

0 · Reply

SuperGreenToday Dec. 23 at 12:35 PM

$NBY

0 · Reply

Money__Hunter Dec. 23 at 3:48 AM

$NBY not my favorite ticker, has a big active shelf for 200mil $, HOWEVER, the following opportunity might play out for another quick scalp (made some money with this on Friday). Will look for a dip to 4.20ish, and if it holds, bounce to 5 is possible with a retest of upper wedge around 6. Very risky play again due to dilution.

1 · Reply

Bullbear1010101 Dec. 23 at 2:20 AM

$NBY 6 is big resistance

0 · Reply

FullPorrtDipz Dec. 23 at 1:21 AM

If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Crazy run coming on $INAB $EVTV $NBY $LPCN

0 · Reply

Z_interceptor Dec. 22 at 11:42 PM

$NBY [ Waiting for this to happen and pay us downside Target 1.20 ]

1 · Reply

CocaKolla Dec. 22 at 9:24 PM

$NBY still holding looks for next leg ⏰

0 · Reply

Market Cap	684.24M
Revenue (ttm)	9.78M
Net Income (ttm)	-7.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-73.82%
Debt to Equity Ratio	0.00

Volume	442,500
Avg Vol	1,100,116
Day's Range	N/A - N/A
Shares Out	126.01M
Stochastic %K	57%
Beta	0.57
Analysts	Hold
Price Target	$0.85